奧洛茲美醫療 HALO 深 滬
等待開盤 03-26 09:30:00 美东时间
63.24
+1.200
+1.93%
華盛通- 最 高63.62
- 今 開62.78
- 成交量 88.21万股
- 最 低 62.69
- 昨 收 62.04
- 總市值 74.62亿
- 52周最高 82.22
- 市盈率 靜 24.73
- 換手率 0.75%
- 52周最低 47.50
- 委 比 -48.49%
- 總股本 1.18亿
- 歷史最高 82.22
- 量 比 0.45
- 振 幅 1.50%
- 歷史最低 3.86
- 每 手 1
- 風險率 7.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Halozyme Therapeutics Announces Johnson & Johnson Gets FDA Approval For TECVAYLI In Combination With DARZALEX FASPRO To Treat Adults With Relapsed Or Refractory Multiple Myeloma
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for TECVAYLI® (teclistamab-cqyv) in combination
03-06 21:01
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression‑free survival and overall survival versus standard of care regimens SAN DIEGO, March 6,...
03-06 21:00
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
Arcutis Biotherapeutics announced the promotion of Mas Matsuda, JD, to executive vice president, chief legal officer, and corporate secretary. Matsuda, previously senior vice president and general counsel, will continue leading the company’s legal, compliance, and governance strategy. He joined Arcutis in 2022 and has supported the commercial growth of ZORYVE, including six FDA approvals. Arcutis is entering a new growth phase, focusing on advanc...
03-05 14:00
美股大行评级 | 潜在涨幅108.69%！Stephens & Co.维持圣玛丽石油勘测"超配"评级，上调目标价至49美元
今日重点评级关注：Stephens & Co.：维持圣玛丽石油勘测"超配"评级，目标价从48美元升至49美元；花旗：维持IDEAYA Biosciences"买入"评级，目标价从64美元升至65美元
02-20 15:57
Benchmark Maintains Buy on Halozyme Therapeutics, Raises Price Target to $90
Benchmark analyst Robert Wasserman maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $75 to $90.
02-20 02:38
Tech Stocks Rebound, Crude Rallies Above $64 On Iran Tensions: What's Moving Markets Wednesday?
Tech stocks recovered on Wednesday, led by a rally in battered software names, as the Nasdaq 100 jumped 1.4% past 25,000, outpacing the S&P 500's 1% gain and the Dow's 0.7% advance.
02-19 02:06
电话会总结 ｜ Halozyme(HALO)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Halozyme业绩会实录，以下是2025年财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 2025年全年总营收14亿美元，同比增长38% - 特许权使用费收入8.678亿美元，同比增长52% - 第四季度总营收4.518亿美元，同比增长52% - 第四季度特许权使用费收入2.58亿美元，同比增长51% **盈利能力：** - 2025年净利润3.169亿美元，较2024年的4.441亿美元下降，主要受Surf Bio收购产生的2.85亿美元IPR&D费用影响 - 调整后EBITDA为6.57亿美元，较2024年的6.322亿美
02-18 12:26
BRIEF-Halozyme Therapeutics Outlook FY Revenue USD 1,385-1,400 Million
BRIEF-Halozyme Therapeutics Outlook FY Revenue USD 1,385-1,400 Million Feb 17 (Reuters) - Halozyme Therapeutics Outlook FY revenue USD 1,385-1,400 million.
02-18 07:50
财报速睇 | 奥洛兹美医疗 2025财年Q4营收4.52亿美元，同比增长51.7%；归母净利润亏损1.42亿美元，由盈转亏
华盛资讯2月18日讯，奥洛兹美医疗公布2025财年Q4业绩，公司Q4营收4.52亿美元，同比增长51.7%，归母净利润亏损1.42亿美元，由盈转亏。
02-18 05:49
Halozyme Therapeutics shares are trading lower after the company reported mixed Q4 financial results.
Halozyme Therapeutics shares are trading lower after the company reported mixed...
02-18 05:15
